{"id":950056,"date":"2026-04-08T18:03:15","date_gmt":"2026-04-08T22:03:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\/"},"modified":"2026-04-08T18:03:15","modified_gmt":"2026-04-08T22:03:15","slug":"ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\/","title":{"rendered":"IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026To Seek Lead Plaintiff Role"},"content":{"rendered":"

<\/p>\n

IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026<\/b>To Seek Lead Plaintiff Role<\/b><\/p>\n

NEW YORK–(BUSINESS WIRE<\/a>)–
\nIf you have suffered a loss on your ImmunityBio, Inc. (\u201cImmunityBio\u201d or the \u201cCompany\u201d) (NASDAQ:IBRX) investment, contact Lauren Molinaro<\/a> of Kirby McInerney LLP by email at investigations@kmllp.com<\/a>, or fill out the contact form below\u00a0to discuss your rights or interests in the securities fraud class action lawsuit at no cost.<\/p>\n

\nInvestors have until May 26, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.<\/p>\n

\n[CONTACT THE FIRM IF YOU SUFFERED A LOSS<\/a>]<\/p>\n

What Is The Lawsuit About?<\/b><\/p>\n

\nThe lawsuit has been filed on behalf of investors who purchased securities during the period of January 19, 2026 through March 24, 2026, inclusive (\u201cthe Class Period\u201d). The lawsuit alleges that (1) Defendant Patrick Soon-Shiong, the Company\u2019s Executive Chairman of the Board, materially overstated the capabilities of Anktiva, an FDA-approved IL-15 receptor agonist immunotherapy that combats cancer, in public statements.<\/p>\n

\nOn March 24, 2026, before markets opened, the United States Food and Drug Administration (\u201cFDA\u201d) issued a warning letter to ImmunityBio. The FDA stated in the warning letter that a TV ad and podcast, which can be accessed through ImmunityBio\u2019s website, has been determined to be \u201cfalse or misleading.\u201d The FDA also stated that \u201cUntitled Letters dated September 9, 2025, and January 7, 2026\u201d were sent to \u201cAltor BioScience, LLC (an indirect wholly-owned subsidiary of ImmunityBio, Inc.) [which] addressed presentations of Anktiva that were, in certain respects, similar to presentations in the TV ad and podcast addressed in this [warning] letter.\u201d \u201c[D]espite receiving these previous Untitled Letters, ImmunityBio continues to promote Anktiva in a similarly misleading manner. On this news, the price of ImmunityBio shares declined by $1.99 per share, or approximately 21.2%, from $9.40 per share on March 23, 2026 to close at $7.41 on March 24, 2026.<\/p>\n

\n[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION<\/a>]<\/p>\n

What Should I Do?<\/b><\/p>\n

\nIf you purchased or otherwise acquired ImmunityBio securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro<\/a> of Kirby McInerney LLP<\/a> by email at investigations@kmllp.com<\/a>, or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.<\/p>\n

\n[WHAT IS A SECURITIES CLASS ACTION?<\/a>]<\/p>\n

Kirby McInerney LLP<\/a> is a New York-based plaintiffs\u2019 law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm\u2019s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP\u2019s website<\/a>.<\/p>\n

\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260408638675\/en\/<\/a><\/span><\/p>\n

\nKirby McInerney LLP
\n
Lauren Molinaro, Esq.
\n
212-699-1171
\n
https:\/\/www.kmllp.com
\n<\/a>
https:\/\/securitiesleadplaintiff.com\/
\n<\/a>
investigations@kmllp.com<\/a><\/p>\n

KEYWORDS:<\/b> New York United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026To Seek Lead Plaintiff Role NEW YORK–(BUSINESS WIRE)– If you have suffered a loss on your ImmunityBio, Inc. (\u201cImmunityBio\u201d or the \u201cCompany\u201d) (NASDAQ:IBRX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below\u00a0to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until May 26, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead … <\/p>\n

Continue reading “IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026To Seek Lead Plaintiff Role”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-950056","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nIBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026To Seek Lead Plaintiff Role - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026To Seek Lead Plaintiff Role - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026To Seek Lead Plaintiff Role NEW YORK–(BUSINESS WIRE)– If you have suffered a loss on your ImmunityBio, Inc. (\u201cImmunityBio\u201d or the \u201cCompany\u201d) (NASDAQ:IBRX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below\u00a0to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until May 26, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead … Continue reading "IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026To Seek Lead Plaintiff Role"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T22:03:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260408638675r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026To Seek Lead Plaintiff Role\",\"datePublished\":\"2026-04-08T22:03:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\\\/\"},\"wordCount\":537,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260408638675r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\\\/\",\"name\":\"IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026To Seek Lead Plaintiff Role - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260408638675r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-04-08T22:03:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260408638675r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260408638675r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026To Seek Lead Plaintiff Role\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026To Seek Lead Plaintiff Role - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\/","og_locale":"en_US","og_type":"article","og_title":"IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026To Seek Lead Plaintiff Role - Market Newsdesk","og_description":"IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026To Seek Lead Plaintiff Role NEW YORK–(BUSINESS WIRE)– If you have suffered a loss on your ImmunityBio, Inc. (\u201cImmunityBio\u201d or the \u201cCompany\u201d) (NASDAQ:IBRX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below\u00a0to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until May 26, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead … Continue reading \"IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026To Seek Lead Plaintiff Role\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-08T22:03:15+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260408638675r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026To Seek Lead Plaintiff Role","datePublished":"2026-04-08T22:03:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\/"},"wordCount":537,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260408638675r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\/","name":"IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026To Seek Lead Plaintiff Role - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260408638675r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-04-08T22:03:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260408638675r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260408638675r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibrx-investor-reminder-immunitybio-inc-investors-have-until-may-26-2026to-seek-lead-plaintiff-role\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026To Seek Lead Plaintiff Role"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/950056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=950056"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/950056\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=950056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=950056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=950056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}